» Articles » PMID: 32427884

Critical Role of SOX2-IGF2 Signaling in Aggressiveness of Bladder Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2020 May 20
PMID 32427884
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Signaling elicited by the stem cell factors SOX2, OCT4, KLF4, and MYC not only mediates reprogramming of differentiated cells to pluripotency but has also been correlated with tumor malignancy. In this study, we found SOX2 expression signifies poor recurrence-free survival and correlates with advanced pathological grade in bladder cancer. SOX2 silencing attenuated bladder cancer cell growth, while its expression promoted cancer cell survival and proliferation. Under low-serum stress, SOX2 expression promoted AKT phosphorylation and bladder cancer cells' spheroid-forming capability. Furthermore, pharmacological inhibition of AKT phosphorylation, using MK2206, inhibited the SOX2-mediated spheroid formation of bladder cancer cells. Gene expression profiling showed that SOX2 expression, in turn, induced IGF2 expression, while SOX2 silencing inhibited IGF2 expression. Moreover, knocking down IGF2 and IGF1R diminished bladder cancer cell growth. Lastly, pharmacological inhibition of IGF1R, using linsitinib, also inhibited the SOX2-mediated spheroid formation of bladder cancer cells under low-serum stress. Our findings indicate the SOX2-IGF2 signaling affects the aggressiveness of bladder cancer cell growth. This signaling could be a promising biomarker and therapeutic target for bladder cancer intervention.

Citing Articles

Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.

Wang Y, Song W, Feng C, Wu S, Qin Z, Liu T J Transl Med. 2024; 22(1):900.

PMID: 39367493 PMC: 11452965. DOI: 10.1186/s12967-024-05685-8.


Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review.

Coelho K, Wosniaki D, Marin A, Fabris L, Dos Reis R, Aoki M Front Oncol. 2024; 14:1441883.

PMID: 39184050 PMC: 11341357. DOI: 10.3389/fonc.2024.1441883.


Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets.

Safder I, Valentine H, Uzzo N, Sfakianos J, Uzzo R, Gupta S JCO Precis Oncol. 2024; 8:e2300661.

PMID: 39151107 PMC: 11371085. DOI: 10.1200/PO.23.00661.


Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review.

Khan I, Kamal A, Akhtar S Cell Biochem Biophys. 2024; 82(3):1907-1929.

PMID: 38954353 DOI: 10.1007/s12013-024-01387-6.


The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.

Griffin R, Shuman L, Yamashita H, Wu Q, Chen G, Brown R Am J Clin Exp Urol. 2024; 12(2):88-99.

PMID: 38736621 PMC: 11087210. DOI: 10.62347/MEQO6014.


References
1.
Yaxley J . Urinary tract cancers: An overview for general practice. J Family Med Prim Care. 2017; 5(3):533-538. PMC: 5290755. DOI: 10.4103/2249-4863.197258. View

2.
Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

3.
Witjes J, Comperat E, Cowan N, De Santis M, Gakis G, Lebret T . EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2013; 65(4):778-92. DOI: 10.1016/j.eururo.2013.11.046. View

4.
Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59(6):1009-18. DOI: 10.1016/j.eururo.2011.03.023. View

5.
Ben-Porath I, Thomson M, Carey V, Ge R, Bell G, Regev A . An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40(5):499-507. PMC: 2912221. DOI: 10.1038/ng.127. View